In these current studies, the administration of a glycoengineered afucosylated (Afuc) αCD39 IgG2c mAb results in overall loss of CD39 expression within the TME, with effective depletion of CD39hi cells (immunosuppressive TAMs and TAECs), which then unleashes immune responsiveness and blocks tumor angiogenesis. Here, ENTPD1 is linked to neoplasm.